Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-Β

S. Naik, R. Nace, Glen N Barber, S. J. Russell

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Multiple myeloma (MM) is an incurable malignancy of plasma secreting B cells disseminated in the bone marrow. Successful utilization of oncolytic virotherapy for myeloma treatment requires a systemically administered virus that selectively destroys disseminated myeloma cells in an immune-competent host. Vesicular stomatitis virus (VSV)-expressing interferon-Β (IFNΒ) is a promising new oncolytic agent that exploits tumor-associated defects in innate immune signaling pathways to destroy cancer cells specifically. We demonstrate here that a single, intravenous dose of VSV coding for IFNΒ (VSV-IFNΒ) specifically destroys subcutaneous and disseminated 5TGM1 myeloma in an immune-competent myeloma model. VSV-IFN treatment significantly prolonged survival in mice bearing orthotopic myeloma. Viral murine IFNΒ expression further delayed myeloma progression and significantly enhanced survival compared with VSV-expressing human IFNΒ. Evaluation of VSV-IFNΒ oncolytic activity in human myeloma cell lines and primary patient samples confirmed myeloma-specific oncolytic activity, but revealed variable susceptibility to VSV-IFNΒ oncolysis. The results indicate that VSV-IFNΒ is a potent, safe oncolytic agent that can be systemically administered to target and destroy disseminated myeloma effectively in immune-competent mice. IFNΒ expression improves cancer specificity and enhances VSV therapeutic efficacy against disseminated myeloma. These data show VSV-IFNΒ to be a promising vector for further development as a potential therapy for the treatment of MM.

Original languageEnglish
Pages (from-to)443-450
Number of pages8
JournalCancer Gene Therapy
Volume19
Issue number7
DOIs
StatePublished - Jul 1 2012

Fingerprint

Vesicular Stomatitis
Multiple Myeloma
Interferons
Viruses
Therapeutics
Neoplasms
Oncolytic Virotherapy
Oncolytic Viruses
Survival
Human Activities
B-Lymphocytes
Bone Marrow
Cell Line

Keywords

  • myeloma
  • oncolytic
  • systemic
  • vesicular stomatitis virus
  • virotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Medicine
  • Molecular Biology

Cite this

Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-Β. / Naik, S.; Nace, R.; Barber, Glen N; Russell, S. J.

In: Cancer Gene Therapy, Vol. 19, No. 7, 01.07.2012, p. 443-450.

Research output: Contribution to journalArticle

@article{783a3d85b431400d9afd520e4cd9d592,
title = "Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-Β",
abstract = "Multiple myeloma (MM) is an incurable malignancy of plasma secreting B cells disseminated in the bone marrow. Successful utilization of oncolytic virotherapy for myeloma treatment requires a systemically administered virus that selectively destroys disseminated myeloma cells in an immune-competent host. Vesicular stomatitis virus (VSV)-expressing interferon-Β (IFNΒ) is a promising new oncolytic agent that exploits tumor-associated defects in innate immune signaling pathways to destroy cancer cells specifically. We demonstrate here that a single, intravenous dose of VSV coding for IFNΒ (VSV-IFNΒ) specifically destroys subcutaneous and disseminated 5TGM1 myeloma in an immune-competent myeloma model. VSV-IFN treatment significantly prolonged survival in mice bearing orthotopic myeloma. Viral murine IFNΒ expression further delayed myeloma progression and significantly enhanced survival compared with VSV-expressing human IFNΒ. Evaluation of VSV-IFNΒ oncolytic activity in human myeloma cell lines and primary patient samples confirmed myeloma-specific oncolytic activity, but revealed variable susceptibility to VSV-IFNΒ oncolysis. The results indicate that VSV-IFNΒ is a potent, safe oncolytic agent that can be systemically administered to target and destroy disseminated myeloma effectively in immune-competent mice. IFNΒ expression improves cancer specificity and enhances VSV therapeutic efficacy against disseminated myeloma. These data show VSV-IFNΒ to be a promising vector for further development as a potential therapy for the treatment of MM.",
keywords = "myeloma, oncolytic, systemic, vesicular stomatitis virus, virotherapy",
author = "S. Naik and R. Nace and Barber, {Glen N} and Russell, {S. J.}",
year = "2012",
month = "7",
day = "1",
doi = "10.1038/cgt.2012.14",
language = "English",
volume = "19",
pages = "443--450",
journal = "Cancer Gene Therapy",
issn = "0929-1903",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-Β

AU - Naik, S.

AU - Nace, R.

AU - Barber, Glen N

AU - Russell, S. J.

PY - 2012/7/1

Y1 - 2012/7/1

N2 - Multiple myeloma (MM) is an incurable malignancy of plasma secreting B cells disseminated in the bone marrow. Successful utilization of oncolytic virotherapy for myeloma treatment requires a systemically administered virus that selectively destroys disseminated myeloma cells in an immune-competent host. Vesicular stomatitis virus (VSV)-expressing interferon-Β (IFNΒ) is a promising new oncolytic agent that exploits tumor-associated defects in innate immune signaling pathways to destroy cancer cells specifically. We demonstrate here that a single, intravenous dose of VSV coding for IFNΒ (VSV-IFNΒ) specifically destroys subcutaneous and disseminated 5TGM1 myeloma in an immune-competent myeloma model. VSV-IFN treatment significantly prolonged survival in mice bearing orthotopic myeloma. Viral murine IFNΒ expression further delayed myeloma progression and significantly enhanced survival compared with VSV-expressing human IFNΒ. Evaluation of VSV-IFNΒ oncolytic activity in human myeloma cell lines and primary patient samples confirmed myeloma-specific oncolytic activity, but revealed variable susceptibility to VSV-IFNΒ oncolysis. The results indicate that VSV-IFNΒ is a potent, safe oncolytic agent that can be systemically administered to target and destroy disseminated myeloma effectively in immune-competent mice. IFNΒ expression improves cancer specificity and enhances VSV therapeutic efficacy against disseminated myeloma. These data show VSV-IFNΒ to be a promising vector for further development as a potential therapy for the treatment of MM.

AB - Multiple myeloma (MM) is an incurable malignancy of plasma secreting B cells disseminated in the bone marrow. Successful utilization of oncolytic virotherapy for myeloma treatment requires a systemically administered virus that selectively destroys disseminated myeloma cells in an immune-competent host. Vesicular stomatitis virus (VSV)-expressing interferon-Β (IFNΒ) is a promising new oncolytic agent that exploits tumor-associated defects in innate immune signaling pathways to destroy cancer cells specifically. We demonstrate here that a single, intravenous dose of VSV coding for IFNΒ (VSV-IFNΒ) specifically destroys subcutaneous and disseminated 5TGM1 myeloma in an immune-competent myeloma model. VSV-IFN treatment significantly prolonged survival in mice bearing orthotopic myeloma. Viral murine IFNΒ expression further delayed myeloma progression and significantly enhanced survival compared with VSV-expressing human IFNΒ. Evaluation of VSV-IFNΒ oncolytic activity in human myeloma cell lines and primary patient samples confirmed myeloma-specific oncolytic activity, but revealed variable susceptibility to VSV-IFNΒ oncolysis. The results indicate that VSV-IFNΒ is a potent, safe oncolytic agent that can be systemically administered to target and destroy disseminated myeloma effectively in immune-competent mice. IFNΒ expression improves cancer specificity and enhances VSV therapeutic efficacy against disseminated myeloma. These data show VSV-IFNΒ to be a promising vector for further development as a potential therapy for the treatment of MM.

KW - myeloma

KW - oncolytic

KW - systemic

KW - vesicular stomatitis virus

KW - virotherapy

UR - http://www.scopus.com/inward/record.url?scp=84863722111&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863722111&partnerID=8YFLogxK

U2 - 10.1038/cgt.2012.14

DO - 10.1038/cgt.2012.14

M3 - Article

VL - 19

SP - 443

EP - 450

JO - Cancer Gene Therapy

JF - Cancer Gene Therapy

SN - 0929-1903

IS - 7

ER -